Kumar Amit, Tanwar Shweta, Gupta Sudhish, Chetiwal Rajesh, Kumar Rohit
Department of Medicine, ESIC Postgraduate Institute of Medical Sciences and Research, Basaidarapur, New Delhi 110015, India.
Scientist C, Indian Council of Medical Research, New Delhi 110029, India.
Explor Target Antitumor Ther. 2022;3(3):392-397. doi: 10.37349/etat.2022.00089. Epub 2022 Jun 29.
Neuroendocrine tumor (NET) is a rare tumor that has been observed in different sites such as lungs and throughout the gastrointestinal tract. Clinical features are usually non-specific and vary considerably depending upon the location of the tumor. Symptoms are similar to those of common conditions such as peptic ulcer disease, gastritis, irritable bowel syndrome, asthma, etc. Thus, an initial diagnosis of a NET usually occurs at an advanced stage. This report describes a case of pancreatic NET (PNET, grade 2) with liver metastasis in a 37-year-old male which was found to be inoperable due to extensive direct involvement of the proximal jejunal branches and superior mesenteric vein. Peptide receptor radionuclide therapy (PRRT) with lutetium-177 dotatate (Lu-DOTATATE) was administered due to the inoperability of primary PNET. Complete resolution of symptoms occurred with three cycles of PRRT.
神经内分泌肿瘤（NET）是一种罕见肿瘤，已在肺部和整个胃肠道等不同部位被观察到。临床特征通常不具有特异性，并且根据肿瘤位置的不同有很大差异。症状与消化性溃疡病、胃炎、肠易激综合征、哮喘等常见病症相似。因此，NET的初始诊断通常发生在晚期。本报告描述了一名37岁男性胰腺神经内分泌肿瘤（PNET，2级）伴肝转移的病例，该病例因近端空肠分支和肠系膜上静脉广泛直接受累而无法手术。由于原发性PNET无法手术，故采用镥-177奥曲肽（Lu-DOTATATE）进行肽受体放射性核素治疗（PRRT）。三个周期的PRRT治疗后症状完全缓解。
